Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Between a Rux and a Hard Place: Investigating Causes of Ruxolitinib Discontinuation, Salvage Treatment and Outcome in Myelofibrosis

Savan Shah, MD, Chetasi Talati, MD, Najla Al Ali, M.Sc, Eric Padron, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Alan F. List, MD, Kenneth S. Zuckerman, MD, Rami S. Komrokji, MD, Andrew Kuykendall, MD

Blood (2017) 130 (Supplement 1): 4186.

https://doi.org/10.1182/blood.V130.Suppl_1.4186.4186

Published: 2017

Journal Articles

Gaining a Better "Sense" for ASXL1 Mutations in Myelofibrosis: Assessing the Variable Impact of Frameshift, Nonsense, and Missense Mutations

Andrew Kuykendall, MD, Jori L Kaplan, MD BA, MA, Chetasi Talati, MD, Najla Al Ali, M.Sc, Kendra L. Sweet, MD, David A Sallman, MD, Eric Padron, MD, Jeffrey E. Lancet, MD, Alan F. List, MD, Kenneth S. Zuckerman, MD, Rami S. Komrokji, MD

Blood (2017) 130 (Supplement 1): 2939.

https://doi.org/10.1182/blood.V130.Suppl_1.2939.2939

Published: 2017

Journal Articles

Effect of NPM1 Mutation on Prognosis and Therapeutic Efficacy in Patients Aged ≥70 Years with Acute Myeloid Leukemia

Chetasi Talati, MD, Andrew Kuykendall, MD, Najla Al Ali, M.Sc, Jongphil Kim, Marina Sehovic, Kenneth S. Zuckerman, MD, David A Sallman, MD, Alan F. List, MD, Eric Padron, MD, Rami S. Komrokji, MD, Benjamin Djulbegovic, MD, Martine Extermann, MD, Kendra Sweet, MD, Jeffrey E. Lancet, MD

Blood (2017) 130 (Supplement 1): 2676.

https://doi.org/10.1182/blood.V130.Suppl_1.2676.2676

Published: 2017

Journal Articles

Hypomethylating Agents Versus Intensive Chemotherapy in Elderly Patients (Age ≥ 70) with Acute Myeloid Leukemia with High White Blood Cell Count

Chetasi Talati, MD, Andrew Kuykendall, MD, Najla Al Ali, M.Sc, Jongphil Kim, Marina Sehovic, Kenneth S. Zuckerman, MD, David A Sallman, MD, Eric Padron, MD, Alan F. List, MD, Rami S. Komrokji, MD, Benjamin Djulbegovic, MD, Martine Extermann, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD

Blood (2017) 130 (Supplement 1): 3911.

https://doi.org/10.1182/blood.V130.Suppl_1.3911.3911

Published: 2017

Journal Articles

Comparison of Survival Outcomes in Elderly Acute Myeloid Leukemia Patients (Age ≥ 70) When Treated with Azacitidine or Decitabine As an Initial Treatment Modality

Chetasi Talati, MD, Andrew Kuykendall, MD, Najla Al Ali, M.Sc, Jongphil Kim, Marina Sehovic, Kenneth S. Zuckerman, MD, David A Sallman, MD, Alan F List, MD, Eric Padron, MD, Rami S. Komrokji, MD, Benjamin Djulbegovic, MD, Martine Extermann, MD, Kendra Sweet, MD, Jeffrey E. Lancet, MD

Blood (2017) 130 (Supplement 1): 3912.

https://doi.org/10.1182/blood.V130.Suppl_1.3912.3912

Published: 2017

Journal Articles

Relative Lymphocytosis Is Associated with Improved Outcome in Myelofibrosis and May Account for the Favorable Prognosis of the Calr mutation

Andrew Kuykendall, MD, Chetasi Talati, MD, Pearlie Epling-Burnette, PhD PharmD, Najla Al Ali, M.Sc, Eric Padron, MD, Kendra L. Sweet, MD, David A Sallman, MD, Jeffrey E. Lancet, MD, Alan F. List, MD, Kenneth S. Zuckerman, MD, Rami S. Komrokji, MD

Blood (2017) 130 (Supplement 1): 1634.

https://doi.org/10.1182/blood.V130.Suppl_1.1634.1634

Published: 2017

Journal Articles

Outcomes in Older Adults (age ≥ 70) with Acute Myeloid Leukemia Based on Choice of Frontline Treatment for Proliferative or Non-Proliferative Phenotype

Blood (2017) 130 (Supplement 1): 1412.

https://doi.org/10.1182/blood.V130.Suppl_1.1412.1412

Published: 2017

Journal Articles

Negative Impact of FLT3-ITD Mutation in Elderly Acute Myeloid Leukemia Patients (Age ≥70) Is Karyotype Dependent

Blood (2017) 130 (Supplement 1): 1413.

https://doi.org/10.1182/blood.V130.Suppl_1.1413.1413

Published: 2017

Journal Articles

Comparing Eras: Assessing Treatment Trends before and after Ruxolitinib Approval

Andrew Kuykendall, MD, Chetasi Talati, MD, Najla Al Ali, Eric Padron, MD, David Sallman, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD, Alan F. List, Kenneth S. Zuckerman, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 3124.

https://doi.org/10.1182/blood.V128.22.3124.3124

Published: 2016

Journal Articles

Monocyte Subset Analysis Accurately Distinguishes Chronic Myelomonocytic Leukemia (CMML) from Myelodysplastic Syndromes (MDS) and Is Associated with a Favorable MDS Prognosis

Chetasi Talati, MD, Ling Zhang, MD, Ghada Shaheen, Andrew Kuykendall, MD, Markus Ball, PhD, Qing Zhang, MD, Jeffrey E. Lancet, MD, Kenneth S. Zuckerman, MD, Alan F. List, MD, Rami S. Komrokji, MD, Lynn C. Moscinski, MD, Eric Padron, MD

Blood (2016) 128 (22): 2009.

https://doi.org/10.1182/blood.V128.22.2009.2009

Published: 2016

Journal Articles

Characterization of Cytogenetic Abnormalities in Myelofibrosis and Relationship to Clinical Outcome

Andrew Kuykendall, MD, Chetasi Talati, MD, Najla H Al Ali, Eric Padron, MD, David Sallman, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD, Alan F. List, Kenneth S. Zuckerman, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 1937.

https://doi.org/10.1182/blood.V128.22.1937.1937

Published: 2016

Journal Articles

Mutation Landscape in Myelofibrosis: Assessment of Frequency and Correlation with Clinical Factors and Outcomes

Andrew Kuykendall, MD, Chetasi Talati, MD, Najla H Al Ali, Eric Padron, MD, David Sallman, MD, Jinming Song, MD PhD, Ling Zhang, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD, Alan F. List, Kenneth S. Zuckerman, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 1946.

https://doi.org/10.1182/blood.V128.22.1946.1946

Published: 2016

Journal Articles

Validation of Genomic-Based Risk Models in Myelofibrosis and Proposal of Age-Independent Disease-Specific Models

Andrew Kuykendall, MD, Chetasi Talati, MD, Najla Al Ali, Eric Padron, MD, David Sallman, MD, Jinming Song, MD PhD, Ling Zhang, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD, Alan F. List, Kenneth S. Zuckerman, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 1947.

https://doi.org/10.1182/blood.V128.22.1947.1947

Published: 2016

Journal Articles

What Is the Impact on Quality of Life of Various Treatments in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome? Rethinking the Goals

Sara M. Tinsley, PhD ARNP, AOCN, Brent J Small, PhD, Jeffrey E Lancet, MD, Susan C McMillan, PhD ARNP, Rami S. Komrokji, MD, Eric Padron, MD, Kenneth S. Zuckerman, MD, Alan F. List, MD

Blood (2015) 126 (23): 2112.

https://doi.org/10.1182/blood.V126.23.2112.2112

Published: 2015

Journal Articles

Clinical Prognostic Factors and Outcomes of Essential Thrombocythemia When Transformed to Myelodysplastic Syndrome and Acute Myeloid Leukemia

Yaman Suleiman, MD, Samir Dalia, MD, Jijun Liu, MD, Jeremy W Bowers, MD, Eric Padron, MD, Jeffrey E Lancet, MD, Lynn C. Moscinski, MD, Rami S Komrokji, MD, Kenneth S. Zuckerman, MD, Ling Zhang, MD

Blood (2014) 124 (21): 1821.

https://doi.org/10.1182/blood.V124.21.1821.1821

Published: 2014

Journal Articles

Clinical Features and Outcome Of Clonal Mastocytosis Secondary To Chronic Myelomonocytic Leukemia (SM- AHNMD/CMML) Given Diverse Therapies – A Single Institution Retrospective Study

Prerna Rastogi, MBBS, PhD, Lynn C. Moscinski, MD, Rami S. Komrokji, MD, Eric Padron, MD, Elizabeth M. Sagatys, MD, Mojdeh Naghashpour, MD, PhD, Jiangchuan Tao, MD, PhD, John M. Bennett, Alan List, MD, Jeffrey E Lancet, MD, Kenneth S. Zuckerman, MD, Ling Zhang, MD

Blood (2013) 122 (21): 4076.

https://doi.org/10.1182/blood.V122.21.4076.4076

Published: 2013

Journal Articles

Primary and Secondary Ocular Adnexal Lymphoma: A Single Institutional Experience

Darcie Deaver, MS, ARNP, Kenneth S. Zuckerman, MD, Celeste M. Bello, MD, Eduardo M. Sotomayor, Salvador Bruno, MD, Lubomir Sokol, MD, PhD

Blood (2011) 118 (21): 4956.

https://doi.org/10.1182/blood.V118.21.4956.4956

Published: 2011

Journal Articles

Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Transformation From Essential Thrombocythemia (ET) In Patients Treated with Hydroxyurea or Anagrelide: A Single Center Series of 17 Cases

Jeremy W Bowers, MD, Jijun Liu, MD, Kenneth S. Zuckerman, MD, Mojdeh Naghashpour, MD, PhD, Jeffrey Lancet, MD, Rami S. Komrokji, MD, Lynn C. Moscinski, MD, Ling Zhang, MD

Blood (2010) 116 (21): 4102.

https://doi.org/10.1182/blood.V116.21.4102.4102

Published: 2010

Journal Articles

Megakaryocyte Production From Feeder Cell-Free Cultures of Human Embryonic Stem Cells (hESC).

Chun Fan, MD, Richard Yunkang Liu, MD, Kristine Li, MS, Qiyuan Keith Liu, PhD, Kenneth S. Zuckerman, MD

Blood (2009) 114 (22): 2528.

https://doi.org/10.1182/blood.V114.22.2528.2528

Published: 2009

NARROW

Between a Rux and a Hard Place: Investigating Causes of Ruxolitinib Discontinuation, Salvage Treatment and Outcome in Myelofibrosis

Gaining a Better "Sense" for ASXL1 Mutations in Myelofibrosis: Assessing the Variable Impact of Frameshift, Nonsense, and Missense Mutations

Effect of NPM1 Mutation on Prognosis and Therapeutic Efficacy in Patients Aged ≥70 Years with Acute Myeloid Leukemia

Hypomethylating Agents Versus Intensive Chemotherapy in Elderly Patients (Age ≥ 70) with Acute Myeloid Leukemia with High White Blood Cell Count

Comparison of Survival Outcomes in Elderly Acute Myeloid Leukemia Patients (Age ≥ 70) When Treated with Azacitidine or Decitabine As an Initial Treatment Modality

Relative Lymphocytosis Is Associated with Improved Outcome in Myelofibrosis and May Account for the Favorable Prognosis of the Calr mutation

Outcomes in Older Adults (age ≥ 70) with Acute Myeloid Leukemia Based on Choice of Frontline Treatment for Proliferative or Non-Proliferative Phenotype

Negative Impact of FLT3-ITD Mutation in Elderly Acute Myeloid Leukemia Patients (Age ≥70) Is Karyotype Dependent

Comparing Eras: Assessing Treatment Trends before and after Ruxolitinib Approval

Monocyte Subset Analysis Accurately Distinguishes Chronic Myelomonocytic Leukemia (CMML) from Myelodysplastic Syndromes (MDS) and Is Associated with a Favorable MDS Prognosis

Characterization of Cytogenetic Abnormalities in Myelofibrosis and Relationship to Clinical Outcome

Mutation Landscape in Myelofibrosis: Assessment of Frequency and Correlation with Clinical Factors and Outcomes

Validation of Genomic-Based Risk Models in Myelofibrosis and Proposal of Age-Independent Disease-Specific Models

What Is the Impact on Quality of Life of Various Treatments in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome? Rethinking the Goals

Clinical Prognostic Factors and Outcomes of Essential Thrombocythemia When Transformed to Myelodysplastic Syndrome and Acute Myeloid Leukemia

Clinical Features and Outcome Of Clonal Mastocytosis Secondary To Chronic Myelomonocytic Leukemia (SM- AHNMD/CMML) Given Diverse Therapies – A Single Institution Retrospective Study

Primary and Secondary Ocular Adnexal Lymphoma: A Single Institutional Experience

Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Transformation From Essential Thrombocythemia (ET) In Patients Treated with Hydroxyurea or Anagrelide: A Single Center Series of 17 Cases

Megakaryocyte Production From Feeder Cell-Free Cultures of Human Embryonic Stem Cells (hESC).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only